Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BillionToOne, Inc. Class A ( (BLLN) ) has provided an update.
On December 8, 2025, BillionToOne’s board of directors expanded by appointing Anthony Pagano as a Class III director and chairperson of the Audit Committee, effective January 1, 2026. This strategic move is expected to strengthen the company’s governance as it continues its growth trajectory. In its third quarter of 2025, BillionToOne reported a significant financial performance with a 117% increase in total revenue compared to the previous year, driven by substantial growth in prenatal and oncology testing revenues. The company also achieved a positive operating income and cash flow, marking a turnaround from the previous year’s losses. BillionToOne’s successful IPO and strong financial results underscore its commitment to innovation and market expansion.
The most recent analyst rating on (BLLN) stock is a Hold with a $117.00 price target. To see the full list of analyst forecasts on BillionToOne, Inc. Class A stock, see the BLLN Stock Forecast page.
More about BillionToOne, Inc. Class A
BillionToOne, Inc. is a next-generation molecular diagnostics company focused on creating powerful and accurate tests that are accessible to all. The company operates primarily in the prenatal and oncology clinical testing markets, aiming to redefine molecular diagnostics with innovative technology and disciplined execution.
Average Trading Volume: 259,588
See more insights into BLLN stock on TipRanks’ Stock Analysis page.